Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial.

MLA

Yim, Hyung Joon, et al. “Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial.” The American Journal of Gastroenterology, vol. 115, no. 8, Aug. 2020, pp. 1217–25. EBSCOhost, https://doi.org/10.14309/ajg.0000000000000605.

APA

Yim, H. J., Kim, W., Ahn, S. H., Yang, J. M., Jang, J. Y., Kweon, Y. O., Cho, Y. K., Kim, Y. J., Hong, G. Y., Kim, D. J., Jung, Y. K., Um, S. H., Sohn, J. H., Lee, J. W., Park, S. J., Lee, B. S., Kim, J. H., Kim, H. S., Yoon, S. K., … Han, K.-H. (2020). Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial. The American Journal of Gastroenterology, 115(8), 1217–1225. https://doi.org/10.14309/ajg.0000000000000605

Chicago

Yim, Hyung Joon, Won Kim, Sang Hoon Ahn, Jin Mo Yang, Jae Young Jang, Yong Oh Kweon, Yong Kyun Cho, et al. 2020. “Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial.” The American Journal of Gastroenterology 115 (8): 1217–25. doi:10.14309/ajg.0000000000000605.